Catalyst Crew Technologies Corp. (OTC: CCTC) announced it has submitted a corporate action request to the Financial Industry Regulatory Authority (FINRA) seeking approval for a proposed corporate name change to LataMed AI Corp. and a corresponding change to its trading symbol. The move is intended to better reflect the company's current strategic direction following its transition toward artificial intelligence-enabled healthcare technology.
The company's strategic focus includes healthcare analytics and technology-enabled healthcare services infrastructure, with an initial emphasis on Latin America. According to the announcement, the proposed corporate action was approved by the company's Board of Directors and by written consent of the majority shareholder in accordance with Nevada law. The company clarified that the proposed action does not involve any reverse stock split, forward stock split, recapitalization, change to authorized capital, or other modification to its capital structure. The issued and outstanding share count will remain unchanged.
Dr. Kevin Rodan Levy, Chief Executive Officer of Catalyst Crew Technologies Corp., stated that the name change is intended to better align the company's public identity with its healthcare technology strategy and long-term market focus. He emphasized that there is no change to the company's capital structure as part of this process. The name change and corresponding trading symbol change will not affect shareholders' ownership interests, and no action will be required by existing shareholders.
Upon FINRA approval, the company intends to file a Certificate of Amendment with the Nevada Secretary of State to effect the corporate name change. The proposed changes would become effective upon completion of the required corporate filings and publication by FINRA on the Daily List. However, the company noted that no assurance can be given that FINRA will approve the proposed name change, the requested new trading symbol, or the timing of any such approval.
This corporate rebranding signals a significant pivot in the company's business model, moving from its previous operations to focus on AI-driven healthcare solutions for emerging markets. The company describes itself as an artificial intelligence-driven healthcare technology company focused on developing scalable digital health solutions for emerging markets, with an initial emphasis on Latin America. Its strategic transition involves pursuing opportunities across telehealth infrastructure, remote patient monitoring, healthcare data analytics, and integrated digital care platforms designed to improve access, efficiency, and care coordination.
The implications of this announcement extend beyond a simple name change. For investors, it represents a clearer alignment between the company's public identity and its operational focus, potentially reducing confusion in the market. For the healthcare technology industry, particularly in Latin America, it signals the entry or strengthened commitment of a publicly-traded entity focusing on AI-enabled solutions that could address regional healthcare challenges. The company's approach through technology development initiatives, strategic partnerships, and targeted acquisitions aims to build an integrated healthcare technology platform to meet growing demand for modernized healthcare delivery systems in emerging markets.
For more information, investors can visit https://catalystcrewai.com or review the company's filings with the U.S. Securities and Exchange Commission at https://www.sec.gov. The company is a development-stage enterprise that has not generated revenues from its newly announced business direction, and its securities involve a high degree of risk. Prospective investors are urged to carefully review all risk factors and disclosures contained in the company's SEC filings before making any investment decision.
